mibavademab

Sponsor Regeneron Pharmaceuticals, INC. · listed as REGN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

mibavademab is a clinical-stage drug asset sponsored by Regeneron Pharmaceuticals, INC., listed as REGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 18, 2027 (day precision, medium confidence), tied to trial NCT07220772. The asset is in Phase 3 and currently recruiting, studied in Monogenic Obesity. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-06-18

As disclosedJun 18, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT07220772

PhasePHASE3

StatusRECRUITING

Lead sponsorRegeneron Pharmaceuticals

Listed asREGN

Condition(s)Monogenic Obesity

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More REGN catalysts